JPRN-jRCT2080224585已完成1 期
A Multicenter, Open-label, Dose-escalation, Phase 1 Trial to Investigate the Tolerability and Safety of ASTX727 in Subjects With Lower-risk Myelodysplastic Syndromes
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Subjects with a definitive diagnosis of MDS and classified as low or Intermediate-1 risk by the International Prognostic Scoring System (IPSS) risk category
- •2) Subjects meeting at least one of the disease-related criteria for Red blood cell (RBC) transfusion, hemoglobin (Hb) ,Absolute neutrophil count,Platelet count within 8 weeks prior to initial administration of IMP
- •3) Subjects with Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1
- •4) Adequate hepatic and renal function
- •5) Sexually active men with reproductive capacity (except those who have undergone bilateral orchidectomy) must agree to use 2 effective contraceptive measures or remain abstinent during the trial and for 3 months after final administration of IMP. Sexually active women of child-bearing potential must agree to use 2 effective contraceptive measures or remain abstinent during the trial and for 6 months after final administration of IMP.
- •6) Subjects who have provided written informed consent using the form approved by the institutional review board
排除标准
- •1) Subjects who have received cytokine therapy, immunosuppressant therapy, or chemotherapy within 4 weeks prior to initial investigational medicinal product (IMP) administration
- •2) Subjects who have received any other IMP or privately-imported medicine within 2 weeks prior to initial IMP administration
- •3) Subjects with deletion 5q who are to be treated with lenalidomide
- •4) Subjects with current or previous bone marrow blast percentage of >10%
- •5) Subjects with a diagnosis of chronic myelomonocytic leukemia
- •6) Subjects with heart disease of New York Heart Association (NYHA) Functional Class 3 or 4
- •7) Subjects with an uncontrolled systemic disease or active uncontrolled infection
- •8) Subjects with diabetes mellitus requiring medical treatment
- •9) Subjects with a life-threatening illness, medical condition or multiple organ dysfunction, or other reason, including laboratory abnormalities, which in the investigator's or subinvestigator's opinion could compromise the subject's safety, interfere with the absorption or metabolism of IMP, or compromise the integrity of the trial outcome
- •10) Subjects with prior malignancy
- •11) Subjects who test positive for human immunodeficiency virus antibody, hepatitis B virus DNA, or hepatitis C virus antibody
- •12) Subjects with a history of surgical gastrectomy
- •13) Subjects with previous organ transplantation
- •14) Subjects with a Grade 2 or more AE attributable to treatment of underlying disease, excluding the AEs
- •15) Subjects who have undergone an invasive and extensive operation within 2 weeks prior to initial IMP administration
- •16) Subjects with hypersensitivity to the IMPs or their excipients
- •17) Subjects with known significant mental illness or other condition, such as active alcohol or other substance abuse or addiction, that in the opinion of the investigator or subinvestigator predisposes the subject to high risk of noncompliance with the protocol
- •18) Female subjects who are pregnant, breast-feeding, or who test positive for pregnancy at screening
研究者
相似试验
已完成
不适用
A multicenter, open-label, dose escalation, Phase I study of LJM716 administered intravenously in combination with trastuzumab in patients with HER2 overexpressing metastatic breast cancer or gastric cancer (CLJM716X2102)breast cancer or gastric cancer10006291NL-OMON37081ovartis Pharma BV3
已完成
不适用
An Open-label, Multicenter, Dose Escalation Phase 1b Study to Assess the Safety and Pharmacokinetics of Subcutaneous Delivery of Daratumumab with the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Subjects with Relapsed or Refractory Multiple MyelomaMultiple Myeloma - plasma cell myeloma10018865NL-OMON50498Janssen-Cilag3
未知
1 期
A multi-center, open-label, dose escalation, Phase 1 study of oral LGH447 in Japanese patients with relapsed and/or refractory hematologic malignanciesMultiple MyelomaJPRN-jRCT2080222538ovartis Pharma K.K.
已完成
1 期
A study of selicrelumab (RO7009789) in combination with atezolizumab in participants with locally advanced and/or metastatic solid tumorsSolid tumorsCancerISRCTN62420110F. Hoffmann-La Roche Ltd140
已完成
1 期
A study of cibisatamab in participants with locally advanced and/or metastatic carcinoembryonic antigen positive solid tumorsCancerISRCTN58060459Genentech, Inc149